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Abstract
Background: In colorectal cancer (CRC), unresectable liver metastases are associated with a poor prognosis. The FOXFIRE
(an open-label randomized phase III trial of 5-fluorouracil, oxaliplatin, and folinic acid +/- interventional radioembolization as
first-line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer), SIRFLOX
(randomized comparative study of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment
in patients with nonresectable liver metastases from primary colorectal carcinoma), and FOXFIRE-Global (assessment of overall
survival of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with
nonresectable liver metastases from primary colorectal carcinoma in a randomized clinical study) clinical trials were designed to
evaluate the efficacy and safety of combining first-line chemotherapy with selective internal radiation therapy (SIRT) using
yttrium-90 resin microspheres, also called transarterial radioembolization.
Objective: The aim of this analysis is to prospectively combine clinical data from 3 trials to allow adequate power to evaluate
the impact of chemotherapy with SIRT on overall survival.
Methods: Eligible patients are adults with histologically confirmed CRC and unequivocal evidence of liver metastases which
are not treatable by surgical resection or local ablation with curative intent at the time of study entry. Patients may also have
limited extrahepatic metastases. Final analysis will take place when all participants have been followed up for a minimum of 2
years.
Results: Efficacy and safety estimates derived using individual participant data (IPD) from SIRFLOX, FOXFIRE, and
FOXFIRE-Global will be pooled using 2-stage prospective meta-analysis. Secondary outcome measures include progression-free
survival (PFS), liver-specific PFS, health-related quality of life, response rate, resection rate, and adverse event profile. The large
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study population will facilitate comparisons of low frequency adverse events and allow for more robust safety analyses. The
potential treatment benefit in those patients who present with disease confined to the liver will be investigated using 1-stage IPD
meta-analysis. Efficacy will be analyzed on an intention-to-treat basis.
Conclusions: This analysis will assess the impact of SIRT combined with chemotherapy on overall survival in the first-line
treatment of metastatic CRC. If positive, the results will change the standard of care for this disease.
Trial Registration: FOXFIRE ISRCTN Registry ISRCTN83867919; http://www.isrctn.com/ISRCTN83867919 (Archived by
WebCite at http://www.webcitation.org/6oN7axrvA). SIRFLOX ClinicalTrials.gov NCT00724503; https://clinicaltrials.gov/
ct2/show/NCT00724503 (Archived by WebCite at http://www.webcitation.org/6oN7lEGbD). FOXFIRE-Global ClinicalTrials.gov
NCT01721954; https://clinicaltrials.gov/ct2/show/NCT01721954 (Archived by WebCite at http://www.webcitation.org/
6oN7vvQvG).
(JMIR Res Protoc 2017;6(3):e43)   doi:10.2196/resprot.7201
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Introduction
The 5-year overall survival (OS) of metastatic colorectal cancer
(mCRC) patients, who constitute 21% of all CRC diagnoses, is
approximately 13% [1]. The liver is the dominant site of
metastases in CRC; liver metastases are the most common cause
of death for patients with CRC [2,3]. To improve outcomes in
mCRC, efforts have been made to increase the proportion of
patients eligible for surgical resection, which is currently 20%
[4-8]. The use of down-staging neoadjuvant chemotherapy in
clinical studies has suggested that 10%-20% of patients with
inoperable liver disease may be converted to candidates for
curative resection [9]. Furthermore, a statistical correlation
between tumor response and resection rates has been found
across clinical studies [10].
Among the liver-directed therapies that may control liver
metastases, selective internal radiation therapy (SIRT) is one
option for patients with liver-only or liver-dominant disease
[11,12]. SIR-Spheres (Sirtex Medical Limited) containing the
β-emitter, yttrium-90, are delivered into the arterial supply of
the liver under fluoroscopic guidance. The delivery of the resin
microspheres into branches of the hepatic artery, which supplies
the majority of blood to liver tumors, results in selective
targeting of the tumor by high-dose radiotherapy, whereas the
healthy liver is supplied predominantly by the portal venous
system and is therefore relatively spared from radiation treatment
[12].
The FOXFIRE (an open-label randomized phase III trial of
5-fluorouracil, oxaliplatin, and folinic acid +/- interventional
radioembolization as first-line treatment for patients with
unresectable liver-only or liver-predominant metastatic
colorectal cancer), SIRFLOX (randomized comparative study
of FOLFOX6m plus SIR-Spheres microspheres versus
FOLFOX6m alone as first-line treatment in patients with
nonresectable liver metastases from primary colorectal
carcinoma), and FOXFIRE-Global (assessment of overall
survival of FOLFOX6m plus SIR-Spheres microspheres versus
FOLFOX6m alone as first-line treatment in patients with
nonresectable liver metastases from primary colorectal
carcinoma in a randomized clinical study) clinical trials were
designed to study SIRT in combination with chemotherapy,
specifically the modified fluorouracil, leucovorin, and oxaliplatin
(FOLFOX) regimen, compared with FOLFOX alone as first-line
therapy for mCRC [13,14]. Eligibility criteria and trial designs
were similar for the 3 trials so that they could be prospectively
combined. The primary and some secondary endpoints of
SIRFLOX have been published, representing the largest
published, randomized, multicenter trial of any liver-directed
therapy in patients with mCRC [15]. The results showed
increased progression-free survival (PFS) in the liver with the
addition of SIRT but no effect of SIRT on overall PFS [15].
The primary objective of the combined analysis is to report the
planned meta-analysis (MA) of individual participant data (IPD)
from the FOXFIRE, SIRFLOX, and FOXFIRE-Global studies
for the primary endpoint, OS, and for secondary outcomes
including PFS, liver-specific PFS, quality of life measures,
response rate, resection rate, and adverse event profile. The
IPD-MA will assess the treatment effects on clinical outcomes
in the entire subject group and in key subgroups.
Methods
Study Design
As the results on survival benefits for each of the 3 studies are
still blinded, the statistical design is a prospective MA based
on randomized IPD from the FOXFIRE, SIRFLOX, and
FOXFIRE-Global clinical trials.
The protocols of the FOXFIRE [13] and SIRFLOX [14] trials
have been previously published. All 3 clinical trials were
open-label multicenter, randomized, 2-arm trials comparing
chemotherapy plus SIRT with chemotherapy alone as first-line
treatment for patients with mCRC. The design of the 3 trials is
summarized in Table 1 and Figure 1.
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Table 1. Characteristics of studies included in the meta-analysis: FOXFIRE [13], SIRFLOX [14], and FOXFIRE-Global.
FOXFIRE-GlobalcSIRFLOXbFOXFIREa
May 20, 2013Oct 11, 2006Nov 13, 2009Start of recruitment
Dec 23, 2014Apr 25, 2013Oct 31, 2014End of recruitment
Dec 23, 2019Apr 25, 2018Oct 31, 2016End of follow-up
698728Number of recruiting centers
Overall survivalProgression-free survivalOverall survivalPrimary objective
Progression-free survival
Progression-free survival in the liver
Toxicity and safety
Tumor response rate
Quality of life
Liver resection rate
Hepatic and extrahepatic recurrence
rate
Health economics
Overall survival
Progression-free survival in the liver
Toxicity and safety
Tumor response rate
Quality of life
Liver resection rate
Hepatic and extrahepatic recurrence
rate
Progression-free survival
Progression-free survival in the liver
Toxicity and safety
Tumor response rate
Quality of life
Liver resection rate
Health costs/economics
Proportion of patients receiving
second line treatment
Time to second line treatment
Secondary objectives
209530364Sample size accrued
May 2013–December 2014October 2006–April 2013November 2009–October 2014Accrual period
December 2014–December 2019April 2013–April 2018November 2014–October 2016Follow-up period
1:1 with minimization1:1 with minimization1:1 with minimizationRandomization
Liver only versus extrahepatic
metastases
Extent of tumor involvement of the
liver (≤25% or >25% determined by
CT scan) and based upon the tumor
involvement groupings used by
Gray et al [16]
Planned use of bevacizumab with
chemotherapy
Investigational center
Liver only versus extrahepatic
metastases
Extent of tumor involvement of the
liver (≤25% or >25% determined by
CT scan) and based upon the tumor
involvement groupings used by
Gray et al [16]
Planned use of bevacizumab with
chemotherapy
Investigational center
Liver only versus extrahepatic
metastases
Extent of tumor involvement of the
liver (≤25% or >25% determined by
CTd scan)
Planned use of biological agent
(from March 2011 on)
Investigational center
Minimization factors
Australia, Europe, Israel, Korea,
New Zealand, Singapore, Taiwan
and United States
Australia, Europe, Israel, New
Zealand, and United States
United Kingdom (England, Northern
Ireland, Scotland, Wales)
Recruiting countries/regions
aAn open-label randomized phase III trial of 5-fluorouracil, oxaliplatin, and folinic acid +/- interventional radioembolization as first-line treatment for
patients with unresectable liver-only or liver-predominant metastatic colorectal cancer.
bRandomized comparative study of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with
nonresectable liver metastases from primary colorectal carcinoma.
cAssessment of overall survival of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with
nonresectable liver metastases from primary colorectal carcinoma in a randomized clinical study.
dComputed tomography.
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Figure 1. Schema for the FOXFIRE, SIRFLOX, and FOXFIRE-Global trials.
Patients and Treatment
All randomized patients from the SIRFLOX, FOXFIRE, and
FOXFIRE-Global clinical trials will be included in the combined
analysis.
Inclusion Criteria
• Histologically confirmed CRC with liver-only or
liver-dominant metastases not amenable to surgical
resection, primary tumour in situ permitted (FOXFIRE);
histologically confirmed CRC with liver-only or
liver-dominant metastases (SIRFLOX); histologically
confirmed adenocarcinoma of the colon or rectum with or
without primary tumor in situ (FOXFIRE-Global)
• Unequivocal and measurable computed tomography (CT)
evidence of liver metastases not treatable by surgical
resection or local ablation with curative intent at time of
trial entry
• Chemotherapy-naïve for mCRC, but previous adjuvant
systemic chemotherapy for primary CRC or neoadjuvant
chemoradiotherapy to the pelvis more than 6 months before
recruitment is permitted (SIRFLOX, FOXFIRE-Global);
eligible for systemic chemotherapy as first-line treatment
for metastatic CRC (FOXFIRE)
• Additional limited extrahepatic metastases in the lung or
lymph nodes permitted (SIRFLOX, FOXFIRE-Global);
patients are permitted to have limited extrahepatic disease
(FOXFIRE)
• Age ≥18 years
• World Health Organization performance status of 0-1
• Life expectancy >3 months
• Adequate hematological, renal, and hepatic function
• Female patients must be postmenopausal or using adequate
contraception if premenopausal, and male patients must be
using an appropriate method of contraception if with a
premenopausal partner (FOXFIRE); female patients must
either be postmenopausal, sterile (surgically or chemically
or radiation-induced) or if sexually active using an
acceptable method of contraception, and male patients must
be surgically sterile or if sexually active and have a
premenopausal partner must be using an acceptable method
of contraception (SIRFLOX, FOXFIRE-Global)
• Suitable for all aspects of treatment determined by clinical
assessment undertaken by investigator
• Willing and able to provide written informed consent
FOXFIRE-Global and SIRFLOX:
• All imaging evidence used as part of the screening process
must be within 28 days prior to randomization
Exclusion Criteria
• Evidence of ascites, cirrhosis, portal hypertension; tumour
involvement of, or thrombosis leading to occlusion of the
main portal vein
• Previous radiotherapy delivered to upper abdomen or upper
lumbar spine (FOXFIRE); previous radiotherapy delivered
to the upper abdomen (SIRFLOX); previous radiotherapy
delivered to the liver (FOXFIRE-Global)
• Nonmalignant disease that would render patient ineligible
at the discretion of the investigator
• Dose-limiting toxicity associated with previous
5-fluorouracil or oxaliplatin chemotherapy
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• Peripheral neuropathy higher than grade 1 (National Cancer
Institute–Common Terminology Criteria for Adverse Events
[NCI-CTCAE] version 3)
• Pregnant or breastfeeding
• Previous chemotherapy for any malignancy; adjuvant
chemotherapy for colorectal cancer is not an exclusion
criterion provided that it was completed more than 6 months
prior to entry into the study (SIRFLOX, FOXFIRE-Global).
Previous chemotherapy for metastatic colorectal cancer;
adjuvant chemotherapy for colorectal cancer is not an
exclusion criterion provided that it was completed more
than 6 months prior to entry into the study (FOXFIRE)
• Concurrent or prior history of cancer other than adequately
treated nonmelanoma skin cancer or carcinoma in situ of
the cervix (SIRFLOX, FOXFIRE-Global); other active
malignancy within last 5 years excluding colorectal cancer
and other nonmelanoma skin cancers (FOXFIRE)
SIRFLOX and FOXFIRE-Global:
Allergy to nonionic contrast agents
FOXFIRE only:
• Liver metastases amenable to curative resection at time of
study entry
• Equivocal, immeasurable, or nonevaluable liver metastases
• Unequivocal evidence of bone metastasis
All patients received first-line chemotherapy for mCRC. In
FOXFIRE, the chemotherapy received was oxaliplatin,
5-fluorouracil, and leucovorin/folic acid in the OxMdG regime
[17]. In SIRFLOX and FOXFIRE-Global, the chemotherapy
consisted of the same drugs in the mFOLFOX6 regime [18].
Patients were randomized 1:1 to the addition of SIRT using
yttrium-90 resin microspheres, using minimization. The
minimization factors are given in Table 1. Biological agents
(cetuximab or bevacizumab in FOXFIRE; bevacizumab in
SIRFLOX) were permitted to be added to chemotherapy at the
treating investigators’ discretion. Protocol treatment in each
study was commenced within 28 days of randomization. Further
details on randomization by minimization and treatment
regimens for FOXFIRE and SIRFLOX have been published
previously [13,14]. FOXFIRE-Global used the same
randomization method and treatment regimen as that used for
the SIRFLOX study.
In all 3 trials, patients were assessed every 2 weeks during
chemotherapy treatment. In SIRFLOX and FOXFIRE-Global,
patients were assessed every 12 weeks during the
postprogression follow-up period. FOXFIRE patients were
assessed every 8 weeks following completion of treatment up
to 18 months and then every 12 weeks thereafter. In all 3 trials,
patients were followed until death or for a period of at least 2
years after randomization. Patients undergoing surgical resection
after trial entry were also followed up until trial closure or until
death.
Screening and follow-up assessments included clinical
assessment and laboratory analyses, recording concurrent
medications, CT scan of the chest/abdomen/pelvis with or
without magnetic resonance imaging, recording adverse events,
assessment for resection or ablation, and questionnaire-based
assessments of quality of life.
Study Outcomes
Primary Outcome of the Combined Analysis
The primary outcome of OS is the time from randomization to
death from any cause, with patients still alive being censored
at their last known follow-up date.
Secondary Outcomes of the Combined Analysis
The secondary outcomes are PFS at any site, liver-specific PFS,
health-related quality of life (HRQoL), response rate, resection
rate, and the safety profiles. PFS is defined as the time from
randomization to radiological progression according to Response
Evaluation Criteria In Solid Tumors (RECIST version 1.0) or
death from any cause, whichever is sooner. Patients who are
not observed to progress or die during the course of the trial
will be censored at last known progression-free follow-up date.
Patients who withdraw from study treatment prior to documented
progression will be censored at the time they commence
nonstudy treatment. Patients who become eligible for resection
will be considered as still being on study until progression is
documented or last follow-up. Scans and tumor response will
be centrally reviewed in FOXFIRE and SIRFLOX.
Liver-specific PFS is defined as the time from randomization
to radiological progression in the liver (hepatic progression)
according to RECIST version 1.0. Progression outside the liver
(extrahepatic progression) and deaths prior to progression will
be considered as competing risks for failure in the liver. Hepatic
progression will be assumed to have occurred immediately
before extrahepatic progression in patients who have identical
hepatic and extrahepatic progression dates. Patients who
withdraw from study treatment prior to any documented
progression will be censored at the time they commence
nonstudy treatment. Patients who become eligible for resection
will be considered as still being on study until progression is
documented or last follow-up.
HRQoL will be assessed using the EuroQol 5 dimensions
questionnaire (EQ-5D). The EQ-5D comprises the following 5
dimensions: mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression. Each of the 5 dimensions is scored,
generating a profile. A single index score or utility value,
representing population-derived preferences for different health
states, will be attached to each profile.
The response rate (objective response) is defined as the number
of patients achieving a complete or partial response according
to RECIST version 1.0 divided by the number of patients in
each treatment arm. Early death by any cause and unknown
responses will be included in the denominator. Response will
be assessed over 2 time periods: within 12 months of
randomization and over follow-up.
The resection rate in each treatment arm is defined as the number
of patients undergoing resection of their liver metastases divided
by the number of patients randomized in each arm. Patients
undergoing treatment are assessed by an experienced liver
multidisciplinary team or equivalent for eligibility for resection
at the discretion of the treating physician.
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The safety profile is assessed by the collection of adverse events
(AEs) and serious adverse events (SAEs) at any time during
treatment with grading using the NCI-CTCAE version 3.
Sample Size Calculation
For the primary combined OS analysis, the FOXFIRE study
protocol details a calculated 1075 patients required using a
protocol-specified hazard ratio (HR) of 0.8, a 36-month accrual
period, and 18-month minimum follow-up with 2-sided 5%
significance, 80% power, and allowing for noncompliance. A
total of 710 deaths are expected. The required sample size had
been previously calculated to be 1022 [13] but was updated to
reflect an estimated increase in median OS in the control group.
As the intervention is a local treatment to the liver only, it is
anticipated that even if there is no OS benefit in the whole
population, a demonstrated survival benefit in the liver-only
subgroup would be clinically meaningful and could change
practice. It is anticipated that, with a 6-month increase in OS in
the SIRT treated liver-only patients compared to those
randomized to chemotherapy only, this would require 463 events
in the liver-only subgroup.
Closure of Study
The final analysis will be undertaken when a minimum of 710
deaths overall and 463 deaths in the liver-only subgroup have
been observed in the pooled dataset and there has been a
minimum follow-up of 2 years since the last patient was
randomized into the 3 trials.
Data Monitoring Committee and Interim Analyses
The independent data and safety monitoring committee
(IDSMC) consisted of the same representatives for the
FOXFIRE, SIRFLOX, and FOXFIRE-Global clinical trials.
Formal interim monitoring of the accumulating data was
performed at regular intervals (approximately every 6 months)
by the IDSMC for each trial separately. This information
included results from other relevant trials but not the analysis
of primary or secondary objectives or outcomes by treatment
groups apart from the prespecified interim analyses. As part of
the review, the IDSMC was asked to justify continued
recruitment of further patients or further follow-up. The IDSMC
advised on the frequency of future reviews of the data on the
basis of accrual and event rates.
The IDSMC reviewed the combined safety data from FOXFIRE
and SIRFLOX at the interim analyses. The following planned
interim analyses were undertaken using combined data from
the FOXFIRE and SIRFLOX trials:
• Analysis of toxicity and safety: 8 months after at least 80
patients were randomized in total (a minimum of 40 per
trial)
• Analysis of toxicity and safety: 8 months after at least 300
patients were randomized in total (a minimum of 120
patients per trial)
The 3 clinical trials that constitute this MA were conducted in
accordance with the Declaration of Helsinki and current Good
Clinical Practice guidelines, and all participating centers
obtained the relevant ethics committee approval before patient
enrollment. FOXFIRE was approved by the National Research
Ethics Service Committee South Central – Berkshire Research
Ethics Committee reference 09/H0505/1 and sponsored by the
University of Oxford. SIRFLOX and FOXFIRE-Global were
approved by the relevant ethics committees for each center and
sponsored by Sirtex Technology Pty Ltd.
Statistical Analysis
Descriptive Summaries
Summaries of baseline factors, including minimization factors,
and percentages of missing data will be reported. Losses to
follow-up will be reported for each trial and combined. Median
follow-up time will be calculated using the reverse Kaplan-Meier
method. Dose of trial-specific treatment delivered and treatment
received subsequent-to-trial treatment will be described.
Efficacy
All efficacy analyses will be performed on an intention-to-treat
(ITT) basis. OS and PFS estimates will be obtained using
Kaplan-Meier survival curves, unadjusted log-rank tests, and
survival models. A 2-stage inverse-variance weighted IPD-MA
will be performed for both OS and PFS, with the first stage
consisting of trial-specific analyses to obtain efficacy estimates
(HRs) and the second stage being a pooled analysis of the
separate trial-specific HRs. As a sensitivity analysis, a 1-stage
IPD-MA using regression models stratified by study will be
performed to confirm the results obtained from the 2-stage
IPD-MA. For each outcome, multivariable models will be used
in the 1-stage IPD-MA to account for baseline covariates.
Liver-specific PFS will be analyzed using cumulative incidence
curves, Gray’s test, and competing risks regression. This analysis
will be performed on the pooled dataset with models stratified
by trial. For OS, PFS, and liver-specific PFS, the potential
treatment benefit in those patients who present with disease
confined to the liver will be investigated. This prespecified
subgroup analysis will be performed on the pooled dataset. The
analysis strategy will include calculating HR for the effect of
treatment in the liver-only subgroup using survival models
stratified by trial.
A separate landmark analysis of OS will start at the 15-month
time point (after randomization) and therefore exclude those
who have died/withdrawn within 15 months of randomization.
This time point has previously been considered of value in
clinical trials of the treatment of mCRC [19]. Based on expert
opinion, it is anticipated that 15 months from baseline allows
sufficient time for events to occur in those with both diagnosed
extrahepatic metastases and subclinical extrahepatic metastases
at baseline, and therefore this analysis may be of value in
detecting any differential survival impact of SIRT in patients
with liver-only metastases.
The EQ-5D data will be merged across all 3 trials and summary
data prepared on the mean EQ-5D utility score in each trial arm
by time period, with appropriate tests for difference. Resection
rate and response rate will be analyzed using chi-square tests
and odds ratios (ORs) for the individual trials and a 2-stage
IPD-MA.
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Safety
Safety analyses will be performed on patients who received at
least 1 dose of chemotherapy in either arm and on an as-treated
basis (safety population). AEs experienced up to 28 days after
the end of trial treatment or 7 months postrandomization,
whichever was earlier, will be included. Descriptive summaries
of the frequency and severity of AEs and the numbers of patients
experiencing AEs of grade 3 or higher between treatment arms
will be presented overall and by system organ class. The Medical
Dictionary for Regulatory Activities version 16.1 is used to
categorize the AEs. Univariate comparisons will be made.
All hypothesis tests will be 2-sided. A significance level of .05
will be used to indicate statistical significance. No missing data
imputation is intended. Missing days in dates may be
appropriately imputed.
Results
Data from the final data lock will become available in January
2017. Data analysis will take place in 2017 with results being
disseminated via peer-reviewed journals in 2017 and 2018.
Discussion
Optimizing outcomes of treatment in patients with nonresectable
liver metastases was identified in an international consensus
expert statement as a key clinical need to be addressed [20].
This is the first extensive investigation of SIRT in the first-line
setting for liver metastases from mCRC adequately powered to
address an overall survival endpoint.
This prospective MA of 3 phase III studies will provide
comprehensive evidence of the safety and potential efficacy of
SIRT in the first-line setting for patients with liver metastases
from mCRC. The results of the SIRFLOX trial published so far
have suggested that the addition of SIRT to chemotherapy can
improve liver-specific PFS [15]. The number of patients
included in this combined analysis and the long-term follow-up,
unprecedented in the field of interventional oncology, will
provide adequate power to address a survival endpoint.
Although the SIRFLOX trial reported that liver-specific PFS
was longer in the SIRT arm than in the control arm, the PFS at
any site was similar between the SIRT arm and the control arm
[15]. This can be accounted for by the fact that SIRT is a
locoregional treatment to the liver only and therefore will not
influence the progression of extrahepatic metastases or
extrahepatic subclinical micrometastases.
It is generally accepted that successful resection of liver
metastases correlates with improved overall survival, particularly
in the context of neoadjuvant or adjuvant chemotherapy [21,22].
Surgery and perioperative chemotherapy are therefore routinely
offered to patients with mCRC if the liver metastases are
resectable. Similarly, the addition of radiofrequency ablation
of liver metastases to standard chemotherapy appears to improve
clinical outcomes for patients compared to those patients
receiving standard chemotherapy alone [23,24]. These findings
with liver-directed therapies suggest that improvement of
liver-specific PFS in patients with liver metastases may correlate
to improvement in OS, an important hypothesis to be tested for
SIRT for the first time in this combined MA of the SIRFLOX,
FOXFIRE, and FOXFIRE-Global trials.
The use of an IPD rather than an aggregate data approach to
systematic review and MA of randomized controlled trials
enables the standardization of outcomes across trials and detailed
data checking, providing a more in-depth exploration and more
robust MA results [25]. The proposed MA, by prospectively
combining IPD from 3 trials, goes beyond classical MA aims
and overrides drawbacks from single trials. The prospective
approach allows for consistent inclusion and exclusion criteria
between studies. The statistical analysis is going to be
standardized across studies, and using IPD-MA will provide
sufficient statistical power to draw conclusions from subgroup
analyses that are generally undermined by low sample size. The
use of the 2-stage approach for the main analyses of OS and
PFS is prespecified, as the 2-stage approach might produce
different parameter estimates to the 1-stage approach, although
the estimates are usually similar [26,27].
The results from the combined analysis of the SIRFLOX,
FOXFIRE, and FOXFIRE-Global trials will provide valuable
clinical information on the efficacy and toxicity profile of SIRT
combined with chemotherapy as a first-line regimen for liver
metastases from mCRC that will guide clinicians in the use of
this technology to treat their patients. The IPD-MA will allow
comparisons of less common AEs that would not be possible
in a smaller population. Furthermore, this prospective MA
provides sufficient power to determine whether SIRT provides
a significant survival benefit for patients with metastases
confined to the liver and no clinically detectable extrahepatic
disease, an important research question among clinicians treating
mCRC. When reported, the results of this combined analysis
will define the use of SIRT in the treatment of mCRC.
 
Acknowledgments
The FOXFIRE trial was developed by the National Cancer Research Institute Colorectal Clinical Study Group and is sponsored
by the University of Oxford. It is supported by the Bobby Moore Fund of Cancer Research United Kingdom (Clinical Trials
Awards and Advisory Committee reference number CRUK/A16630), an educational grant from Sirtex Medical Ltd, and by the
National Institute for Health Research Biomedical Research Center Oxford. The SIRFLOX and FOXFIRE-Global studies are
sponsored by Sirtex Technology Pty Ltd.
JMIR Res Protoc 2017 | vol. 6 | iss. 3 | e43 | p.7http://www.researchprotocols.org/2017/3/e43/
(page number not for citation purposes)
Virdee et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
The FOXFIRE Trial Management and Quality Assurance Group: Adil Al-Nahhas, Dave Berry, Ian Chau, Luise Dunham, David
Kerr, Nas Khan, Val Lewington, Rachel Midgley, Bruno Morgan, Sarah Pearson, Anne Roberts, Will Steward, Paul Tait, Greg
Wilson, Andy Wotherspoon.
FOXFIRE Health Economists: Alastair Gray, Jane Wolstenholme.
The FOXFIRE Study Group: Richard Adams, Andrew Bateman, Claire Blesing, Ewan Brown, Ian Chau, Sebastian Cummins,
David Cunningham, Stephen Falk, Maher Hadaki, Marcia Hall, Tamas Hickish, Joanne Hornbuckle, Fiona Lofts, Sarah Lowndes,
Astrid Mayer, Matthew Metcalfe, Gary Middleton, Jamie Mills, Amir Montazeri, Rebecca Muirhead, Andreas Polychronis, Colin
Purcell, Paul Ross, Liz Sherwin, David Smith, Rubin Soomal, Daniel Swinson, Axel Walther, Andrew Weaver, Charles Wilson,
Greg Wilson. We would also like to thank the University of Oxford statisticians Susan Dutton and Peter Dutton for their
contributions to the FOXFIRE study.
The SIRFLOX and FOXFIRE-Global Study Group: Steven Ades, Morteza Aghmesheh, Pradip Amin, Bruna Angelelli, Miklos
Auber, Jacques Balosso, Alex Beny, Daniel Bloomgarden, Patrick Boland, Eveline Boucher, Christoph Bremer, Michael Brown,
Harald-Robert Bruch, James Bui, Matthew Burge, Giuseppe Cardaci, James Carlisle, Ruiz Casado, Yi-Jen Chen, Patrick Chevallier,
Michael Chuong, Stephen Clarke, Prasad Cooray, Andrew Coveler, Michel Craninx, Thierry Delanoit, Amélie Deleporte, Kyran
Dowling, Aurelie Durand, Paul Eliadis, Francis Facchini, Kynan Feeney, Thomas Ferguson, Michel Ferrante, Aurelie Ferru,
Michael Findlay, Maria Fragoso, Gary Frenette, Jacob Frick, Vinod Ganju, Michael Garofalo, Karen Geboes, Gerald Gehbauer,
Benjamin George, Ravit Geva, Michael Gordon, Cristina Granetto, Kate Gregory, Seza Gulec, Pascal Hammel, James Hannigan,
Norman Heching, Volker Heinemann, Thomas Helmberger, Alain Hendlisz, Koen Hendrickx, Matthew Holtzman, Ayala Hubert,
Richard Isaacs, Christopher Jackson, Philip James, Adeel Kaiser, Chris Karapetis, Andreas Kaubisch, Yeul Hong Kim, Yon-Dschun
Ko, Todd Kooy, Hendrik Kröning, Frank Lammert, Jin Tung Liang, Winston Liauw, Lionel Lim, Yoo Joo Lim, Jin Hwang Liu,
Samy Louafi, Marc de Man, Jeffrey Margolis, Robert Martin, Andrea Martoni, Gavin Marx, Marco Matos, Els Monsaert, Veerle
Moons, Stefania Mosconi, Louise Nott, Arnd Nusch, Anne O’Donnell, Howard Ozer, Siddarth Padia, Nick Pavlakis, Marc Peeters,
David Perez, Stefan Pluntke, Marc Polus, Alex Powell, Marc Pracht, Timothy Price, Jorge Ramon, David Ransom, Christine
Rebischung, Jens Ricke, Karsten Ridwelski, Hanno Riess, Jorge Ramon Riera, William Rilling, Bridget Robinson, Javier Rodríguez,
Federico Sanchez, Tilmann Sauerbruch, Michael Savin, Klemens Scheidhauer, Elyse Schneiderman, Grant Seeger, Eva Segelov,
Einat Shaham Schmueli, Adi Shani, Jenny Shannon, Navesh Sharma, Stephen Shibata, Nimit Singhal, Denis Smith, Randall
Smith, Salomon Stemmer, Oliver Stötzer, Andrew Strickland, Julien Taieb, Iain Tan, Klaus Tatsch, Eric Terrebonne, Thomas
Tichler, Antonio Trogu, Craig Underhill, Daniel Van Daele, Ursula Vehling-Kaiser, Ruth Vera-Garcia, Caterina Vivaldi, Thomas
Vogl, Euan Walpole, Eric Wang, Mark Westcott, Samuel Whiting, Ido Wolf.
The authors acknowledge Bruce Gray for his involvement in the development of the initial SIRFLOX protocol and the editorial
assistance provided by Martin Gilmour and Thierry Deltheil of ESP Bioscience (Crowthorne, United Kingdom) during the
preparation of this manuscript.
Authors' Contributions
RAS and HSW conceived the FOXFIRE study and secured the funding for the investigator-initiated study. SBL and JM provided
statistical advice. All authors read and approved the final draft of the manuscript for submission. PG, VG, and GVH were
substantially involved in the conception and design of the SIRFLOX and FOXFIRE-Global studies. EAF coordinated the FOXFIRE
study during the patient follow-up period. All authors were involved in critically reviewing the manuscript for important intellectual
content, and all authors read and approved the final draft of the manuscript for submission.
Conflicts of Interest
RAS has received research funding, honoraria, and consultancy fees from Sirtex Medical Ltd. PG has received honoraria from
Sirtex for participation in advisory boards and for giving presentations. VG and GVH have received compensation for participation
in advisory committees from Sirtex. PSV, JM, HSW, EAF, and SBL declare no competing interests.
References
1. Surveillance, Epidemiology, and End Results Stat Fact Sheets: Colon and Rectum Cancer, 2003-2009. 2013. URL: https:/
/seer.cancer.gov/statfacts/html/colorect.html [accessed 2016-12-15] [WebCite Cache ID 6mmB3DsTx]
2. Abbas S, Lam V, Hollands M. Ten-year survival after liver resection for colorectal metastases: systematic review and
meta-analysis. ISRN Oncol 2011 [FREE Full text] [doi: 10.5402/2011/763245] [Medline: 22091431]
3. Helling TS, Martin M. Cause of death from liver metastases in colorectal cancer. Ann Surg Oncol 2014 Feb;21(2):501-506.
[doi: 10.1245/s10434-013-3297-7] [Medline: 24081807]
4. Rothbarth J, van de Velde CJH. Treatment of liver metastases of colorectal cancer. Ann Oncol 2005;16 Suppl 2:ii144-ii149
[FREE Full text] [doi: 10.1093/annonc/mdi702] [Medline: 15958446]
JMIR Res Protoc 2017 | vol. 6 | iss. 3 | e43 | p.8http://www.researchprotocols.org/2017/3/e43/
(page number not for citation purposes)
Virdee et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
5. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases
to the liver: a prospective study. J Clin Oncol 2005 Mar 01;23(7):1358-1364. [doi: 10.1200/JCO.2005.12.039] [Medline:
15684312]
6. Navarra G, Ayav A, Weber J, Jensen SL, Smadga C, Nicholls JP, et al. Short- and long-term results of intraoperative
radiofrequency ablation of liver metastases. Int J Colorectal Dis 2005 Nov;20(6):521-528. [doi: 10.1007/s00384-005-0743-4]
[Medline: 15864606]
7. Van Cutsem E, Nordlinger B, Adam R, Köhne C, Pozzo C, Poston G, European Colorectal Metastases Treatment Group.
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006
Sep;42(14):2212-2221. [doi: 10.1016/j.ejca.2006.04.012] [Medline: 16904315]
8. Jones RP, Poston GJ. Resection of liver metastases in colorectal cancer in the era of expanding systemic therapy. Annu
Rev Med 2016 Sep 28. [doi: 10.1146/annurev-med-062415-093510] [Medline: 27686016]
9. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, et al. Oxaliplatin, fluorouracil, and
leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment
Group phase II study. J Clin Oncol 2005 Dec 20;23(36):9243-9249. [doi: 10.1200/JCO.2005.07.740] [Medline: 16230673]
10. Folprecht G, Grothey A, Alberts S, Raab H, Köhne C. Neoadjuvant treatment of unresectable colorectal liver metastases:
correlation between tumour response and resection rates. Ann Oncol 2005 Aug;16(8):1311-1319 [FREE Full text] [doi:
10.1093/annonc/mdi246] [Medline: 15870084]
11. Nicolay NH, Berry DP, Sharma RA. Liver metastases from colorectal cancer: radioembolization with systemic therapy.
Nat Rev Clin Oncol 2009 Dec;6(12):687-697. [doi: 10.1038/nrclinonc.2009.165] [Medline: 19884901]
12. Wang LM, Jani AR, Hill EJ, Sharma RA. Anatomical basis and histopathological changes resulting from selective internal
radiotherapy for liver metastases. J Clin Pathol 2013 Mar;66(3):205-211 [FREE Full text] [doi:
10.1136/jclinpath-2012-201231] [Medline: 23162108]
13. Dutton SJ, Kenealy N, Love SB, Wasan HS, Sharma RA, FOXFIRE Protocol Development Group and the NCRI Colorectal
Clinical Study Group. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and
folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment
for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer 2014 Jul 09;14:497
[FREE Full text] [doi: 10.1186/1471-2407-14-497] [Medline: 25011439]
14. Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA. Selective Internal Radiation Therapy (SIRT)
with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as
first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. BMC Cancer 2014 Dec
01;14:897 [FREE Full text] [doi: 10.1186/1471-2407-14-897] [Medline: 25487708]
15. van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Peeters M, et al. SIRFLOX: randomized phase III trial
comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus
selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 2016 May 20;34(15):1723-1731.
[doi: 10.1200/JCO.2015.66.1181] [Medline: 26903575]
16. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomised trial of SIR-Spheres plus chemotherapy
versus chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001
Dec;12(12):1711-1720 [FREE Full text] [Medline: 11843249]
17. Shimizu T, Satoh T, Tamura K, Ozaki T, Okamoto I, Fukuoka M, et al. Oxaliplatin/fluorouracil/leucovorin (FOLFOX4
and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population
experience. Int J Clin Oncol 2007 Jun;12(3):218-223. [doi: 10.1007/s10147-007-0658-x] [Medline: 17566846]
18. Braun MS, Adab F, Bradley C, McAdam K, Thomas G, Wadd NJ, et al. Modified de Gramont with oxaliplatin in the
first-line treatment of advanced colorectal cancer. Br J Cancer 2003 Oct 06;89(7):1155-1158 [FREE Full text] [doi:
10.1038/sj.bjc.6601237] [Medline: 14520437]
19. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in
stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011 Jan 01;29(1):11-16 [FREE
Full text] [doi: 10.1200/JCO.2010.30.0855] [Medline: 20940184]
20. Clary BM, Grothey A, Kopetz S, Marsh RDW. Systemic cytotoxic and biologic therapies for colorectal cancer liver
metastases: expert consensus statement. HPB (Oxford) 2013 Feb;15(2):116-118 [FREE Full text] [doi:
10.1111/j.1477-2574.2012.00598.x] [Medline: 23297722]
21. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, EORTC Gastro-Intestinal Tract Cancer Group,
Cancer UK, Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO),
Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD).
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal
cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013
Nov;14(12):1208-1215. [doi: 10.1016/S1470-2045(13)70447-9] [Medline: 24120480]
22. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy
as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS
randomised clinical trials. Eur J Cancer 2012 Jul;48(10):1466-1475. [doi: 10.1016/j.ejca.2012.02.057] [Medline: 22446022]
JMIR Res Protoc 2017 | vol. 6 | iss. 3 | e43 | p.9http://www.researchprotocols.org/2017/3/e43/
(page number not for citation purposes)
Virdee et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
23. Ruers T, Punt C, Van Coevorden F, Pierie JPEN, Borel-Rinkes I, Ledermann JA, EORTC Gastro-Intestinal Tract Cancer
Group, Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO),
National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG). Radiofrequency ablation combined
with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a
randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012 Oct;23(10):2619-2626 [FREE Full text]
[doi: 10.1093/annonc/mds053] [Medline: 22431703]
24. Ruers T, Cornelis J, Punt C, Van Coevorden F, Pierie J, Rinkes I, et al. Radiofrequency ablation (RFA) combined with
chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase
II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). J Clin Oncol 2015;33(Suppl):A3501.
25. Tierney JF, Vale C, Riley R, Smith CT, Stewart L, Clarke M, et al. Individual participant data (IPD) meta-analyses of
randomised controlled trials: guidance on their use. PLoS Med 2015 Jul;12(7):e1001855 [FREE Full text] [doi:
10.1371/journal.pmed.1001855] [Medline: 26196287]
26. Debray TPA, Moons KGM, Abo-Zaid GMA, Koffijberg H, Riley RD. Individual participant data meta-analysis for a binary
outcome: one-stage or two-stage? PLoS One 2013;8(4):e60650 [FREE Full text] [doi: 10.1371/journal.pone.0060650]
[Medline: 23585842]
27. Stewart GB, Altman DG, Askie LM, Duley L, Simmonds MC, Stewart LA. Statistical analysis of individual participant
data meta-analyses: a comparison of methods and recommendations for practice. PLoS One 2012;7(10):e46042 [FREE
Full text] [doi: 10.1371/journal.pone.0046042] [Medline: 23056232]
Abbreviations
AE: adverse event
CRC: colorectal cancer
CT: computed tomography
EQ-5D: EuroQol 5 dimensions questionnaire
FOLFOX: modified fluorouracil, leucovorin, and oxaliplatin regimen
FOXFIRE: An open-label randomized phase III trial of 5-fluorouracil, oxaliplatin, and folinic acid +/- interventional
radioembolization as first-line treatment for patients with unresectable liver-only or liver-predominant metastatic
colorectal cancer
FOXFIRE-Global: Assessment of overall survival of FOLFOX6m plus SIR-Spheres microspheres versus
FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal
carcinoma in a randomized clinical study
HR: hazard ratio
HRQoL: health-related quality of life
IDSMC: independent data and safety monitoring committee
IPD: individual participant data
IPD-MA: Individual participant data meta-analysis
ITT: intention-to-treat
MA: meta-analysis
mCRC: metastatic colorectal cancer
NCI-CTCAE: National Cancer Institute–Common Terminology Criteria for Adverse Events
OR: odds ratio
OS: overall survival
PFS: progression-free survival
RECIST: Response Evaluation Criteria In Solid Tumors
SAE: serious adverse events
SIRFLOX: Randomized comparative study of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m
alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma
SIRT: selective internal radiation therapy
JMIR Res Protoc 2017 | vol. 6 | iss. 3 | e43 | p.10http://www.researchprotocols.org/2017/3/e43/
(page number not for citation purposes)
Virdee et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Edited by G Eysenbach; submitted 20.12.16; peer-reviewed by A Kennedy, T Helmberger; comments to author 11.01.17; revised
version received 19.01.17; accepted 21.01.17; published 28.03.17
Please cite as:
Virdee PS, Moschandreas J, Gebski V, Love SB, Francis EA, Wasan HS, van Hazel G, Gibbs P, Sharma RA
Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/-
Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer
JMIR Res Protoc 2017;6(3):e43
URL: http://www.researchprotocols.org/2017/3/e43/ 
doi:10.2196/resprot.7201
PMID:28351831
©Pradeep S Virdee, Joanna Moschandreas, Val Gebski, Sharon B Love, E Anne Francis, Harpreet S Wasan, Guy van Hazel,
Peter Gibbs, Ricky A Sharma. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 28.03.2017.
This is an open-access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information,
a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be
included.
JMIR Res Protoc 2017 | vol. 6 | iss. 3 | e43 | p.11http://www.researchprotocols.org/2017/3/e43/
(page number not for citation purposes)
Virdee et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
